Abstract
The pathological features of breast cancer diagnosed during pregnancy have been analyzed in numerous studies. Because of the retrospective nature of such studies and the paucity of casecontrol studies it is impossible to directly compare the biological properties of breast cancer in pregnant and nonpregnant patients of similar age. The vast majority of breast cancers are invasive ductal (Woo et al. 2003). It is likely that, in addition to larger tumor diameters and more frequent involvement of the regional lymph nodes, breast cancers in pregnancy are characterized by poor differentiation and low expression of estrogen and progesterone receptors (Fig. 5.1) (Bonnier et al. 1997; Gentilini et al. 2004; Middleton et al. 2003; Miller et al. 2005; Reed et al. 2003; Ring et al. 2005); a recent review identified 13 studies reporting estrogen receptors in breast cancers diagnosed during pregnancy; estrogen receptors were negative in 138 of 235 patients (59%, 95% confidence interval 52%–65%) (Woo et al. 2003). The proportion of breast cancers with overexpression of HER-2 protein was similar in pregnant and in young nonpregnant patients (Aziz et al. 2003; Colleoni et al. 2002; Middleton et al. 2003).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson BO, Petrek JA, Byrd DR et al. (1996) Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Ann Surg Oncol 3: 204–211
Aviles A and Neri N (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2: 173–177
Aziz S, Pervez S, Khan S et al. (2003) Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma. Pathol Res Pract 199: 15–21
Barthelmes L and Gateley CA (2004) Tamoxifen and pregnancy. Breast 13: 446–451
Barthelmes L, Davidson LA, Gaffney C et al. (2005) Pregnancy and breast cancer. BMJ 330: 1375–1378
Bonnier P, Romain S, Dilhuydy JM et al. (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 72: 720–727
Bradley B, Fleck A, Osei EK (2006) Normalized data for the estimation of fetal radiation dose from radiotherapy of the breast. Br J Radiol 79: 818–827
Cancer Care Ontario (2006) Breast Cancer Evidence-based Series and Practice Guidelines, Vol. 2006, Cancer Care Ontario
Cardonick E and Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5: 283–291
Carlson RW, Anderson BO, Burstein HJ et al. (2006) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer
Chang YT, Loong CC, Wang HC et al. (1994) Breast cancer and pregnancy. Zhonghua Yi Xue Za Zhi (Taipei) 54: 223–229
Colleoni M, Bonetti M, Coates AS et al. (2000) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18: 584–590
Colleoni M, Rotmensz N, Robertson C et al. (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13: 273–279
Culbert EC and Schfirin BS (2006) Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789–791
Cullins SL, Pridjian G, Sutherland CM (1994) Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA 271: 1905–1906
Cunha GR, Taguchi O, Namikawa R et al. (1987) Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol 18: 1132–1143
Cuvier C, Espie M, Extra JM et al. (1997) Vinorelbine in pregnancy. Eur J Cancer 33: 168–169
De Santis M, Lucchese A, De Carolis S et al. (2000) Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 9: 235–237
Diel IJ, Solomayer EF, Costa SD et al. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357–363
Einarson A, Maltepe C, Navioz Y et al. (2004) The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 111: 940–943
Fanale MA, Uyei AR, Theriault RL et al. (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6: 354–356
Gadducci A, Cosio S, Fanucchi A et al. (2003) Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 23: 5225–5229
Gentilini O, Cremonesi M, Trifiro G et al. (2004) Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 15: 1348–1351
Giacalone PL, Laffargue F, Benos P (1999) Chemotherapy for breast carcinoma during pregnancy: A French national survey. Cancer 86: 2266–2272
Goldhirsch A, Glick JH, Gelber RD et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569–1583
Guinee VF, Olsson H, Moller T et al. (1994) Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343: 1587–1589
Hahn KM, Johnson PH, Gordon N et al. (2006) Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107: 1219–1226
Hebert-Croteau N, Freeman CR, Latreille J et al. (2004) A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Cancer Res Treat 88: 187–196
Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976–983
Hershman DL, Wang X, McBride R et al. (2006) Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65: 1353–1360
Ibrahim EM, Ezzat AA, Baloush A et al. (2000) Pregnancy-associated breast cancer: a case-control study in a young population with a high-fertility rate. Med Oncol 17: 293–300
Illidge TM, Hussey M, Godden CW (1996) Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257–258
Isaacs RJ, Hunter W, Clark K (2001) Tamoxifen as systemic treatment of advanced breast cancer during pregnancy—case report and literature review. Gynecol Oncol 80: 405–408
Ishida T, Yokoe T, Kasumi F et al. (1992) Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res 83: 1143–1149
Kal HB and Struikmans H (2005) Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 6: 328–333
Kaufmann M, Hortobagyi GN, Goldhirsch A et al. (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940–1949
Kelly H, Graham M, Humes E et al. (2006) Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 7: 339–341
Kremer LC, van Dalen EC, Offringa M et al. (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19: 191–196
Kremer LC, van der Pal HJ, Offringa M et al. (2002a) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13: 819–829
Kremer LCM, van Dalen EC, Offringa M et al. (2002b) Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 13: 503–512.
Loibl S, von Minckwitz G, Gwyn K et al. (2006). Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 106: 237–246
Mamounas EP, Bryant J, Lembersky B et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23: 3686–3696
Martin M, Pienkowski T, Mackey J et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302–2313
Mazonakis M, Varveris H, Damilakis J et al. (2003) Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 55: 386–391
Meyer-Wittkopf M, Barth H, Emons G et al. (2001) Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol 18: 62–66
Middleton LP, Amin M, Gwyn K et al. (2003) Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98: 1055–1060
Miller KD, Chap LI, Holmes FA et al. (2005) Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799
Nieto Y, Santisteban M, Aramendia JM et al. (2006) Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clin Breast Cancer 6: 533–534
Nugent P and O’Connell TX (1985) Breast cancer and pregnancy. Arch Surg 120: 1221–1224
Oksuzoglu B and Guler N (2002) An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 104: 79
Oktay K, Buyuk E, Libertella N et al. (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23: 4347–4353
Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev: CD003474
Petrek JA, Dukoff R, Rogatko A (1991) Prognosis of pregnancy-associated breast cancer. Cancer 67: 869–872
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672
Potluri V, Lewis D, Burton GV (2006) Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature. Clin Breast Cancer 7: 167–170
Powles T, Paterson A, McCloskey E et al. (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8: R13
Reed W, Hannisdal E, Skovlund E et al. (2003). Pregnancy and breast cancer: a population-based study. Virchows Arch 443: 44–50
Ring AE, Smith IE, Jones A et al. (2005) Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 23: 4192–4197
Roché H, Fumoleau P, Spielmann M et al. (2004) Five-year analysis of the PACS 01 trial: 6 cycles of FEC100 cs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 88 Suppl 1: S16
Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684
Say L, Kulier R, Gulmezoglu M et al. (2005) Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev: CD003037
Slamon D, Eiermann W, Robert N et al. (2005) Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. Breast Cancer Res Treat 89, Suppl. 1: S5 (Abstract #1)
Smith IE, Dowsett M, Yap YS et al. (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24: 2444–2447
Tewari K, Bonebrake RG, Asrat T et al. (1997) Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350 :183
Vujovic O, Yu E, Cherian A et al. (2006) Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys 64: 760–764
Waterston AM and Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24: 321–322.
Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105: 642–643
Woo JC, Yu T, Hurd TC (2003) Breast cancer in pregnancy: a literature review. Arch Surg 138: 91–98; discussion 99
Zemlickis D, Lishner M, Degendorfer P et al. (1996) Maternal and fetal outcome following breast cancer in pregnancy. In Cancer in pregnancy. Maternal and fetal risks., Koren, G., Lishner, M. & Farine, D. (eds) pp. 95–115. Cambridge University Press: New York
Zemlickis D, Lishner M, Degendorfer P et al. (1992) Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 166: 781–787
Zhang J, Liu G, Wu J et al. (2003) Pregnancy-associated breast cancer: a case control and long-term follow-up study in China. J Exp Clin Cancer Res 22: 23–27
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Aebi, S., Loibl, S. (2008). Breast Cancer During Pregnancy: Medical Therapy and Prognosis. In: Cancer and Pregnancy. Recent Results in Cancer Research, vol 178. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71274-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-71274-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71272-5
Online ISBN: 978-3-540-71274-9
eBook Packages: MedicineMedicine (R0)